Change Edition

Pfizer-BioNTech vaccine cleared for 12-15 year olds in Europe
Vaccines

Pfizer-BioNTech vaccine cleared for 12-15 year olds in Europe

28.05.2021 From our online archive
European Medicines Agency approves use of shot for children aged 12 and over
The Pfizer-BioNTech vaccine
The Pfizer-BioNTech vaccine
Photo credit: dpa

European regulators have cleared Pfizer/BioNTech’s Covid-19 vaccine for children aged 12 and over, preparing the way for mass inoculations of younger teenagers across the continent.

The European Medicines Agency is expanding authorisation of the shot, which is already cleared for people as young as 16, it said in a statement on Friday. The green light gives Europe, whose immunisation campaign was initially fraught with difficulties, the first vaccine in its arsenal for younger children.

“It’s an important step in the fight against the pandemic,” said Marco Caveleri, the regulator’s head of biological health threats and vaccines strategy.

Germany, Europe’s largest economy, has already outlined plans to inoculate younger teens and will expand inoculations to those ages 12 and older starting June 7.

Europe is following US regulators, who authorised the vaccine for young teens earlier this month. President Joe Biden has since asked states to make shots available immediately to help children return to schools and summer camps safely.

New York-based Pfizer and Germany’s BioNTech said in March that their two-shot Comirnaty-branded vaccine was 100% effective in the 12-to-15 age group in a final-stage trial. The shot produced antibodies exceeding the level in vaccinated young adults and didn’t result in any new or worrisome side effects.

The duo sought authorisation from the EMA at the end of April. Caveleri said trials raised no major concerns about using the shot on adolescents.

The 27-nation EU is relying on Pfizer and BioNTech to help it accelerate an immunisation campaign that still lags behind the UK and US, even after gaining ground in recent weeks. The bloc has committed to buying another 1.8 billion doses from the partners through 2023, some of which will be used for children.

“Now we have data that show the vaccine is safe also in the age of 12-15 years,” Cavaleri said. “It will be up to each individual member state to decide if and when to use the vaccine in adolescents in the future.” He added that he expects Moderna to seek authorisation to use its shot for teens soon.

©2021 Bloomberg L.P.


The Luxembourg Times has a new LinkedIn page, follow us here! Get the Luxembourg Times delivered to your inbox twice a day. Sign up for your free newsletters here.


More on this topic